1.Carter CL, Allen C, Henson DE: Relation of tumor size, lymph node status, and survival in 24,740 breast cancer cases. Cancer 1989, 63(1):181–187.
2.de Boer M, van Dijck JA, Bult P, Borm GF, Tjan-Heijnen VC: Breast cancer prognosis and occult lymph node metastases, isolated tumor cells, and micrometastases. J Natl Cancer Inst 2010, 102(6):410–425.
3.Rao R, Euhus D, Mayo HG, Balch C: Axillary node interventions in breast cancer: a systematic review. JAMA 2013, 310(13):1385–1394.
4.Choi HY, Park M, Seo M, Song E, Shin SY, Sohn YM: Preoperative Axillary Lymph Node Evaluation in Breast Cancer: Current Issues and Literature Review. Ultrasound Q 2017, 33(1):6–14.
5.Valente SA, Levine GM, Silverstein MJ, Rayhanabad JA, Weng-Grumley JG, Ji L, Holmes DR, Sposto R, Sener SF: Accuracy of predicting axillary lymph node positivity by physical examination, mammography, ultrasonography, and magnetic resonance imaging. Ann Surg Oncol 2012, 19(6):1825–1830.
6.Alvarez S, Anorbe E, Alcorta P, Lopez F, Alonso I, Cortes J: Role of sonography in the diagnosis of axillary lymph node metastases in breast cancer: a systematic review. AJR Am J Roentgenol 2006, 186(5):1342–1348.
7.Lee SC, Jain PA, Jethwa SC, Tripathy D, Yamashita MW: Radiologist’s role in breast cancer staging: providing key information for clinicians. Radiographics 2014, 34(2):330–342.
8.Kutomi G, Ohmura T, Satomi F, Takamaru T, Shima H, Suzuki Y, Otokozawa S, Zembutsu H, Mori M, Hirata K: Lymph node shape in computed tomography imaging as a predictor for axillary lymph node metastasis in patients with breast cancer. Exp Ther Med 2014, 8(2):681–685.
9.Uematsu T, Sano M, Homma K: In vitro high-resolution helical CT of small axillary lymph nodes in patients with breast cancer: correlation of CT and histology. AJR Am J Roentgenol 2001, 176(4):1069–1074.
10.Kuijs VJ, Moossdorff M, Schipper RJ, Beets-Tan RG, Heuts EM, Keymeulen KB, Smidt ML, Lobbes MB: The role of MRI in axillary lymph node imaging in breast cancer patients: a systematic review. Insights Imaging 2015, 6(2):203–215.
11.Al-Hattali S, Vinnicombe SJ, Gowdh NM, Evans A, Armstrong S, Adamson D, Purdie CA, Macaskill EJ: Breast MRI and tumour biology predict axillary lymph node response to neoadjuvant chemotherapy for breast cancer. Cancer Imaging 2019, 19(1):91.
12.Zhou P, Wei Y, Chen G, Guo L, Yan D, Wang Y: Axillary lymph node metastasis detection by magnetic resonance imaging in patients with breast cancer: A meta-analysis. Thorac Cancer 2018, 9(8):989–996.
13.de Meric de Bellefon M, Lemanski C, Ducteil A, Fenoglietto P, Azria D, Bourgier C: Management of the Axilla in the Era of Breast Cancer Heterogeneity. Front Oncol 2018, 8:84.
14.Donker M, van Tienhoven G, Straver ME, Meijnen P, van de Velde CJ, Mansel RE, Cataliotti L, Westenberg AH, Klinkenbijl JH, Orzalesi L et al: Radiotherapy or surgery of the axilla after a positive sentinel node in breast cancer (EORTC 10981–22023 AMAROS): a randomised, multicentre, open-label, phase 3 non-inferiority trial. Lancet Oncol 2014, 15(12):1303–1310.
15.Giuliano AE, Hunt KK, Ballman KV, Beitsch PD, Whitworth PW, Blumencranz PW, Leitch AM, Saha S, McCall LM, Morrow M: Axillary dissection vs no axillary dissection in women with invasive breast cancer and sentinel node metastasis: a randomized clinical trial. JAMA 2011, 305(6):569–575.
16.Shirzadi A, Mahmoodzadeh H, Qorbani M: Assessment of sentinel lymph node biopsy after neoadjuvant chemotherapy for breast cancer in two subgroups: Initially node negative and node positive converted to node negative - A systemic review and meta-analysis. J Res Med Sci 2019, 24:18.
17.Ditsch N, Untch M, Kolberg-Liedtke C, Jackisch C, Krug D, Friedrich M, Janni W, Muller V, Albert US, Banys-Paluchowski M et al: AGO Recommendations for the Diagnosis and Treatment of Patients with Locally Advanced and Metastatic Breast Cancer: Update 2020. Breast Care (Basel) 2020, 15(3):294–309.
18.Boughey JC, Suman VJ, Mittendorf EA, Ahrendt GM, Wilke LG, Taback B, Leitch AM, Kuerer HM, Bowling M, Flippo-Morton TS et al: Sentinel lymph node surgery after neoadjuvant chemotherapy in patients with node-positive breast cancer: the ACOSOG Z1071 (Alliance) clinical trial. JAMA 2013, 310(14):1455–1461.
19.Caudle AS, Yang WT, Krishnamurthy S, Mittendorf EA, Black DM, Gilcrease MZ, Bedrosian I, Hobbs BP, DeSnyder SM, Hwang RF et al: Improved Axillary Evaluation Following Neoadjuvant Therapy for Patients With Node-Positive Breast Cancer Using Selective Evaluation of Clipped Nodes: Implementation of Targeted Axillary Dissection. J Clin Oncol 2016, 34(10):1072–1078.
20.Veronesi U, Paganelli G, Viale G, Luini A, Zurrida S, Galimberti V, Intra M, Veronesi P, Robertson C, Maisonneuve P et al: A randomized comparison of sentinel-node biopsy with routine axillary dissection in breast cancer. N Engl J Med 2003, 349(6):546–553.
21.von Minckwitz G, Huang CS, Mano MS, Loibl S, Mamounas EP, Untch M, Wolmark N, Rastogi P, Schneeweiss A, Redondo A et al: Trastuzumab Emtansine for Residual Invasive HER2-Positive Breast Cancer. N Engl J Med 2019, 380(7):617–628.
22.Masuda N, Lee SJ, Ohtani S, Im YH, Lee ES, Yokota I, Kuroi K, Im SA, Park BW, Kim SB et al: Adjuvant Capecitabine for Breast Cancer after Preoperative Chemotherapy. N Engl J Med 2017, 376(22):2147–2159.
23.Johnston SRD, Harbeck N, Hegg R, Toi M, Martin M, Shao ZM, Zhang QY, Martinez Rodriguez JL, Campone M, Hamilton E et al: Abemaciclib Combined With Endocrine Therapy for the Adjuvant Treatment of HR+, HER2-, Node-Positive, High-Risk, Early Breast Cancer (monarchE). J Clin Oncol 2020, 38(34):3987–3998.
24.Bakker MF, de Lange SV, Pijnappel RM, Mann RM, Peeters PHM, Monninkhof EM, Emaus MJ, Loo CE, Bisschops RHC, Lobbes MBI et al: Supplemental MRI Screening for Women with Extremely Dense Breast Tissue. N Engl J Med 2019, 381(22):2091–2102.
25.Veronesi U, Cascinelli N, Mariani L, Greco M, Saccozzi R, Luini A, Aguilar M, Marubini E: Twenty-year follow-up of a randomized study comparing breast-conserving surgery with radical mastectomy for early breast cancer. N Engl J Med 2002, 347(16):1227–1232.
26.van der Voort A, van Ramshorst MS, van Werkhoven ED, Mandjes IA, Kemper I, Vulink AJ, Oving IM, Honkoop AH, Tick LW, van de Wouw AJ et al: Three-Year Follow-up of Neoadjuvant Chemotherapy With or Without Anthracyclines in the Presence of Dual ERBB2 Blockade in Patients With ERBB2-Positive Breast Cancer: A Secondary Analysis of the TRAIN–2 Randomized, Phase 3 Trial. JAMA Oncol 2021.
27.Tolaney SM, Barry WT, Dang CT, Yardley DA, Moy B, Marcom PK, Albain KS, Rugo HS, Ellis M, Shapira I et al: Adjuvant paclitaxel and trastuzumab for node-negative, HER2-positive breast cancer. N Engl J Med 2015, 372(2):134–141.
28.Mariotto A, Jayasekerea J, Petkov V, Schechter CB, Enewold L, Helzlsouer KJ, Feuer EJ, Mandelblatt JS: Expected Monetary Impact of Oncotype DX Score-Concordant Systemic Breast Cancer Therapy Based on the TAILORx Trial. J Natl Cancer Inst 2020, 112(2):154–160.
29.Huang M, O’Shaughnessy J, Zhao J, Haiderali A, Cortes J, Ramsey SD, Briggs A, Hu P, Karantza V, Aktan G et al: Association of Pathologic Complete Response with Long-Term Survival Outcomes in Triple-Negative Breast Cancer: A Meta-Analysis. Cancer Res 2020, 80(24):5427–5434.
30.Tutt ANJ, Garber JE, Kaufman B, Viale G, Fumagalli D, Rastogi P, Gelber RD, de Azambuja E, Fielding A, Balmana J et al: Adjuvant Olaparib for Patients with BRCA1- or BRCA2-Mutated Breast Cancer. N Engl J Med 2021.
31.Swarnkar PK, Tayeh S, Michell MJ, Mokbel K: The Evolving Role of Marked Lymph Node Biopsy (MLNB) and Targeted Axillary Dissection (TAD) after Neoadjuvant Chemotherapy (NACT) for Node-Positive Breast Cancer: Systematic Review and Pooled Analysis. Cancers (Basel) 2021, 13(7).
32.Simons JM, Koppert LB, Luiten EJT, van der Pol CC, Samiei S, de Wilt JHW, Siesling S, Smidt ML: De-escalation of axillary surgery in breast cancer patients treated in the neoadjuvant setting: a Dutch population-based study. Breast Cancer Res Treat 2020, 180(3):725–733.
33.Flores-Funes D, Aguilar-Jimenez J, Martinez-Galvez M, Ibanez-Ibanez MJ, Carrasco-Gonzalez L, Gil-Izquierdo JI, Aguayo-Albasini JL: The problem of axillary staging in breast cancer after neoadjuvant chemotherapy. Role of targeted axillary dissection and types of lymph node markers. Cir Esp (Engl Ed) 2020, 98(9):510–515.
34.Choi HJ, Ryu JM, Kim I, Nam SJ, Kim SW, Yu J, Lee JE, Lee SK: Prediction of axillary pathologic response with breast pathologic complete response after neoadjuvant chemotherapy. Breast Cancer Res Treat 2019, 176(3):591–596.
35.Caparica R, Lambertini M, Ponde N, Fumagalli D, de Azambuja E, Piccart M: Post-neoadjuvant treatment and the management of residual disease in breast cancer: state of the art and perspectives. Ther Adv Med Oncol 2019, 11:1758835919827714.
36.Okello J, Kisembo H, Bugeza S, Galukande M: Breast cancer detection using sonography in women with mammographically dense breasts. BMC Med Imaging 2014, 14:41.
37.Rezvani A, Zahergivar A, Iranpour P, Akrami M, Kazemi S: Diagnostic Accuracy of Axillary Ultrasonography Compared with Intra-operative Pathological Findings in Patients with Breast Cancer. Asian Pac J Cancer Prev 2018, 19(12):3615–3621.
38.Riedel F, Schaefgen B, Sinn HP, Feisst M, Hennigs A, Hug S, Binnig A, Gomez C, Harcos A, Stieber A et al: Diagnostic accuracy of axillary staging by ultrasound in early breast cancer patients. Eur J Radiol 2021, 135:109468.
39.Tsai WC, Lin CK, Wei HK, Yu BL, Hung CF, Cheng SH, Chen CM: Sonographic elastography improves the sensitivity and specificity of axilla sampling in breast cancer: a prospective study. Ultrasound Med Biol 2013, 39(6):941–949.
40.Chang W, Jia W, Shi J, Yuan C, Zhang Y, Chen M: Role of Elastography in Axillary Examination of Patients With Breast Cancer. J Ultrasound Med 2018, 37(3):699–707.
41.Luo N, Su D, Jin G, Liu L, Zhu X, Xie D, Liu Y: Apparent diffusion coefficient ratio between axillary lymph node with primary tumor to detect nodal metastasis in breast cancer patients. J Magn Reson Imaging 2013, 38(4):824–828.
42.Baltzer PA, Dietzel M, Burmeister HP, Zoubi R, Gajda M, Camara O, Kaiser WA: Application of MR mammography beyond local staging: is there a potential to accurately assess axillary lymph nodes? evaluation of an extended protocol in an initial prospective study. AJR Am J Roentgenol 2011, 196(5):W641–647.
43.Marino MA, Avendano D, Zapata P, Riedl CC, Pinker K: Lymph Node Imaging in Patients with Primary Breast Cancer: Concurrent Diagnostic Tools. Oncologist 2020, 25(2):e231-e242.
44.Yuen S, Yamada K, Goto M, Sawai K, Nishimura T: CT-based evaluation of axillary sentinel lymph node status in breast cancer: value of added contrast-enhanced study. Acta Radiol 2004, 45(7):730–737.
45.Wang L, Li Y, Li J, Wang T, Xie Y, He Y, Fan Z, Ouyang T: Computed tomography reconstruction for evaluating response in axillary lymph nodes of breast cancer after neoadjuvant chemotherapy. Clin Transl Oncol 2021, 23(2):240–245.
46.Zhao YX, Liu YR, Xie S, Jiang YZ, Shao ZM: A Nomogram Predicting Lymph Node Metastasis in T1 Breast Cancer based on the Surveillance, Epidemiology, and End Results Program. J Cancer 2019, 10(11):2443–2449.
47.Mann RM, Kuhl CK, Moy L: Contrast-enhanced MRI for breast cancer screening. J Magn Reson Imaging 2019, 50(2):377–390.